DFTX Chief Commercial Officer Matthew Wiley Sells $129K of Stock

Matthew Wiley, the Chief Commercial Officer of Definium Therapeutics, Inc. (NasdaqGS: DFTX), sold 2,867 shares of the company on June 25, 2026. The shares were sold at an average price of $45.03, amounting to a total transaction value of approximately $129,101.01. This transaction was executed under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stock.

Insider Buying and Selling at Definium Therapeutics, Inc.

On June 25, 2026, several executives at Definium Therapeutics, including CEO Robert Barrow and Chief Medical Officer Daniel Karlin, also sold shares under similar planned transactions. Robert Barrow sold 29,208 shares, and Daniel Karlin sold 10,035 shares, both at the same average price of $45.03 per share. Chief Legal Officer Mark Sullivan and Chief Financial Officer Brandi Roberts also participated in these planned sales, disposing of 13,008 and 3,013 shares respectively. Earlier, on June 22, 2026, Daniel Karlin bought 100,000 shares in an unplanned transaction, indicating ongoing insider activity.

Definium Therapeutics, Inc. Stock Up 15.8%

Shares of Definium Therapeutics traded near $44.95 on Saturday. The company, with a market capitalization of around $5.97 billion, operates in the biotechnology sector, focusing on treatments for brain health disorders. Despite a negative forward P/E ratio of -28.83 due to its unprofitability, the stock has shown volatility with a beta of 2.378. It has a 52-week range between $6.40 and $47.01, with moving averages of $24.52 over 50 days and $17.07 over 200 days. The company maintains a strong liquidity position with a current ratio of 4.69 and a quick ratio of 4.60.

Analysts Set New Price Targets

Analysts remain optimistic about Definium Therapeutics. On June 24, 2026, Jones Trading maintained a 'buy' rating with a price target of $74. Similarly, Baird and Needham reaffirmed their 'buy' ratings with targets of $57 and $50, respectively, on June 23, 2026. Leerink Partners and Oppenheimer also continued their positive outlooks, setting targets of $52 and $60. The consensus among 15 analysts is a 'strong buy', with an average target price of $56.

About Definium Therapeutics

Definium Therapeutics, Inc. is a biotechnology company based in New York, New York. It focuses on developing innovative treatments for brain health disorders. The company is advancing DT120, a phase 3 candidate for anxiety and depression, and DT402, a phase 2a candidate for autism spectrum disorder. With 105 employees, the company is led by CEO Robert Barrow. Originally known as Mind Medicine (MindMed) Inc., it rebranded to Definium Therapeutics in January 2026.

Bottom Line

Matthew Wiley's recent stock sale is part of a planned transaction, providing insight into insider activity at Definium Therapeutics. Definium's stock performance reflects its high volatility and significant market interest, as seen through the various 'buy' ratings from analysts. Investors continue to watch Definium closely, particularly given its focus on high-need therapeutic areas and ongoing clinical developments.